- Home
- LE vs FHTX Comparison
LE vs FHTX Comparison
Compare LE & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- FHTX
- Stock Information
- Founded
- LE 1963
- FHTX 2015
- Country
- LE United States
- FHTX United States
- Employees
- LE N/A
- FHTX N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- LE Consumer Discretionary
- FHTX Health Care
- Exchange
- LE Nasdaq
- FHTX Nasdaq
- Market Cap
- LE 280.4M
- FHTX 278.1M
- IPO Year
- LE N/A
- FHTX 2020
- Fundamental
- Price
- LE $14.40
- FHTX $5.77
- Analyst Decision
- LE Strong Buy
- FHTX Strong Buy
- Analyst Count
- LE 2
- FHTX 6
- Target Price
- LE $20.00
- FHTX $11.33
- AVG Volume (30 Days)
- LE 329.8K
- FHTX 84.1K
- Earning Date
- LE 09-09-2025
- FHTX 11-03-2025
- Dividend Yield
- LE N/A
- FHTX N/A
- EPS Growth
- LE N/A
- FHTX N/A
- EPS
- LE 0.14
- FHTX N/A
- Revenue
- LE $1,338,672,000.00
- FHTX $24,173,000.00
- Revenue This Year
- LE $3.31
- FHTX $43.75
- Revenue Next Year
- LE $2.34
- FHTX $1.27
- P/E Ratio
- LE $105.89
- FHTX N/A
- Revenue Growth
- LE N/A
- FHTX N/A
- 52 Week Low
- LE $7.65
- FHTX $2.95
- 52 Week High
- LE $19.88
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- LE 62.03
- FHTX 58.68
- Support Level
- LE $13.56
- FHTX $5.14
- Resistance Level
- LE $14.87
- FHTX $5.46
- Average True Range (ATR)
- LE 0.64
- FHTX 0.37
- MACD
- LE 0.02
- FHTX 0.05
- Stochastic Oscillator
- LE 80.25
- FHTX 99.03
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.